<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05088343</url>
  </required_header>
  <id_info>
    <org_study_id>SHR8735-110</org_study_id>
    <nct_id>NCT05088343</nct_id>
  </id_info>
  <brief_title>Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects</brief_title>
  <official_title>A Single-centre, Open, Single-dose, Self-control Study to Investigate the Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Chinese Adult Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effect of hetrombopag on the pharmacokinetics of rosuvastatin in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the study is to evaluate the effect of hetrombopag on&#xD;
      pharmacokinetics of healthy Chinese adult subjects after oral administration of rosuvastatin&#xD;
      calcium tablets. The secondary objective of the study is to evaluate the safety of&#xD;
      rosuvastatin alone and when co-administered with hetrombopag.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 7, 2020</start_date>
  <completion_date type="Actual">January 16, 2021</completion_date>
  <primary_completion_date type="Actual">January 16, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>rosuvastatin alone and then in combination with hetrombopag</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak plasma concentration (Cmax)</measure>
    <time_frame>0-72 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the plasma concentration vs time curve (AUC0-72)</measure>
    <time_frame>0-72 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the blood concentration vs time curve (AUC0-inf)</measure>
    <time_frame>0-infinity</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other pharmacokinetics parameters of rosuvastatin</measure>
    <time_frame>0-72 hours post dose</time_frame>
    <description>Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of volunteers with adverse events as a measure of safety and tolerability</measure>
    <time_frame>up to Day 20</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rosuvastatin alone and then in combination with hetrombopag</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Single oral dose of rosuvastatin on Day 1 or co-administered with hetrombopag on Day 11.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hetrombopag</intervention_name>
    <description>7.5 mg hetrombopag was administered on Day 6 to Day 11.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Sign the informed consent before the trial, and fully understand the trial content,&#xD;
             process and possible adverse reactions;&#xD;
&#xD;
          -  Ability to complete the study as required by the protocol;&#xD;
&#xD;
          -  Healthy male or female subjects aged 18 to 55 (including 18 and 55) at the date of&#xD;
             signing the informed consent;&#xD;
&#xD;
          -  Male body weight ≥ 50 kg, female body weight ≥ 45 kg, and body mass index (BMI) within&#xD;
             the range of 19 ~ 26 kg /m2 (including 19 and 26).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergic constitution;&#xD;
&#xD;
          -  History of drug use, or drug abuse screening positive;&#xD;
&#xD;
          -  Alcoholic or often drinkers;&#xD;
&#xD;
          -  History of deep vein thrombosis, or any other thromboembolic event;&#xD;
&#xD;
          -  A clear medical history of important primary organ diseases such as nervous system,&#xD;
             cardiovascular system, urinary system, digestive system, respiratory system,&#xD;
             metabolism and musculoskeletal system.&#xD;
&#xD;
          -  Abnormal clinical laboratory tests and clinical significance judged by the&#xD;
             investigator or other clinical findings showing the following diseases, including but&#xD;
             not limited to gastrointestinal tract, kidney, liver, nerve, blood, endocrine, tumor,&#xD;
             lung, immune, mental or cardiovascular and cerebrovascular diseases.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xueying Ding</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xueying General Ding</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 25, 2021</study_first_submitted>
  <study_first_submitted_qc>October 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2021</study_first_posted>
  <last_update_submitted>October 10, 2021</last_update_submitted>
  <last_update_submitted_qc>October 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

